Antibody News and Research

RSS

An antibody is a blood protein that is produced in response to and counteracts an antigen. Antibodies are produced in response to disease and help the body fight against the particular disease. In this way, antibodies help the body develop an immunity to disease.

Sensational proteomics results enabled by Bruker’s new IMPACT HD™ Mass Spectrometer with Novel CaptiveSpray™ nanoBooster Ion Source

At the 61st ASMS conference, Bruker introduces exciting new High-Definition capabilities in proteomics and biomarker research. Patented low-noise Captivespray nanoBooster™ ionization coupled with record high-speed digitization Qq-TOF technology and steered by intelligent acquisition software defines complex samples more sharply than ever before.

10 Jun 2013

NanoViricides files Orphan Drug application with FDA for DengueCide

NanoViricides, Inc. announced today that it has filed an Orphan Drug application with the Office of Orphan Product Development of the US FDA for DengueCide, its drug candidate for the treatment of dengue and dengue hemorrhagic fever.

10 Jun 2013

New revolutionary HIV test provides results in one minute

On Saturday, June 8th, AIDS Healthcare Foundation (AHF) will make history as the first HIV testing program in New York City to use a revolutionary HIV test that provides results to people in just one minute.

7 Jun 2013

Cow antibodies points to new ways for making human medicines

Humans have been raising cows for their meat, hides and milk for millennia. Now it appears that the cow immune system also has something to offer. A new study led by scientists from The Scripps Research Institute (TSRI) focusing on an extraordinary family of cow antibodies points to new ways to make human medicines.

7 Jun 2013

New technique for developing complex protein drugs from bacteria

A cheaper, more efficient technique for developing complex protein drugs from bacteria has been developed at the University of Sheffield.

6 Jun 2013

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

Medicago Inc., a biopharmaceutical company focused on developing highly effective and competitive vaccines based on proprietary manufacturing technologies and Virus-Like Particles, today reported positive interim results from a preclinical trial for an H7N9 Avian Influenza VLP vaccine candidate ("H7 vaccine").

6 Jun 2013

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

CytomX Therapeutics, Inc., a biotechnology company developing a new generation of targeted antibody therapeutics, today announced that it has entered into a global strategic collaboration with Pfizer Inc. to develop and commercialize multiple Probody-Drug Conjugates.

6 Jun 2013

Cells with amplified HER2 gene need to be considered carefully, study says

Biocept, Inc., a privately-held, CLIA certified laboratory testing company focused on detection and analysis of circulating tumor cells and circulating tumor DNA in cancer patients, reported the publication in the journal Cancer Medicine of a paper entitled "Discordance in HER2 gene amplification in circulating and disseminated tumor cells in patients with operable breast cancer" on research performed with collaborators from the University of Texas MD Anderson Cancer Center.

5 Jun 2013

Bioengineers find innovative ways to grow new cartilage from patient's own stem cells

Cartilage injuries are difficult to repair. Current surgical options generally involve taking a piece from another part of the injured joint and patching over the damaged area, but this approach involves damaging healthy cartilage, and a person's cartilage may still deteriorate with age.

5 Jun 2013

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy

Colorectal cancer (CRC) is the second most frequent cause of cancer-related mortality in both Europe and the United States. Treatment for patients with resectable hepatic metastases from colorectal cancer consists of surgery combined with chemotherapy, but recurrence is observed in two thirds of these patients.

5 Jun 2013

New technique selectively represses unwanted immune reactions without disabling immune system

The human immune system is remarkably efficient, but sometimes its attack is misdirected, leading to allergies, autoimmune diseases and rejection of transplant organs and therapeutic drugs. Current immune suppressants have major drawbacks, but a team from The Scripps Research Institute (TSRI) has demonstrated a new technique that may lead to a better way to selectively repress unwanted immune reactions without disabling the immune system as a whole.

4 Jun 2013

Cancer immunotherapy shows promise in treating patients with metastatic tumors

Cancer immunotherapy is showing promise in treating patients with a variety of advanced, metastatic tumors, as evidenced by two newly unveiled studies from Yale Cancer Center.

4 Jun 2013

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

OncoMed Pharmaceuticals, Inc., a privately held, clinical-stage company developing novel therapeutics that target cancer stem cells, or tumor-initiating cells, today highlighted new data for vantictumab, a monoclonal antibody targeting the Wnt pathway, at a poster session at the Annual Meeting of the American Society for Clinical Oncology in Chicago, IL.

4 Jun 2013

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Precision Biologics, in collaboration with investigators from Duke University, has been selected to present an abstract of findings from its Phase 2 clinical trial at the Annual Meeting of the American Society of Clinical Oncology.

4 Jun 2013

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

Researchers at Dartmouth-Hitchcock Norris Cotton Cancer Center will present a poster on a phase I clinical trial of Nivolumab, a PD-1 receptor blocking antibody, being used in combination with other drugs in patients with metastatic renal cell carcinoma at the ASCO Annual Meeting on June 3, 2013.

4 Jun 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

ImmunoGen, Inc., a biotechnology company that develops anticancer therapeutics using its Targeted Antibody Payload ADC technology, today announced the presentation of the first clinical data with the Company's IMGN853 product candidate.

3 Jun 2013

New drug shows promising results with manageable side effects for treating melanoma

Researchers from UCLA's Jonsson Comprehensive Cancer Center report that a new drug in preliminary tests has shown promising results with very manageable side effects for treating patients with melanoma, the deadliest form of skin cancer.

3 Jun 2013

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

The combination of the immunotherapy drug ipilimumab and the investigational antibody drug nivolumab led to long-lasting tumor shrinkage in more than half of patients with metastatic melanoma, according to results from a Phase I trial simultaneously published online on Sunday, June 2, in The New England Journal of Medicine and presented by Memorial Sloan-Kettering Cancer Center researchers at the 49th Annual Meeting of the American Society of Clinical Oncology (ASCO).

3 Jun 2013

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

The angiogenesis inhibitor bevacizumab (Avastin) failed to increase overall survival (OS) or statistically significant progression-free survival (PFS) for glioblastoma patients in the frontline setting, according to research led by researchers at The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Study investigates gene expression signature to predict response to bevacizumab

A new test may help identify newly diagnosed glioblastoma patients more likely to benefit from bevacizumab (Avastin-), according to new research from The University of Texas MD Anderson Cancer Center.

3 Jun 2013

Antibody News and Research

Further Reading

Sensational proteomics results enabled by Bruker’s new IMPACT HD™ Mass Spectrometer with Novel CaptiveSpray™ nanoBooster Ion Source

NanoViricides files Orphan Drug application with FDA for DengueCide

New revolutionary HIV test provides results in one minute

Cow antibodies points to new ways for making human medicines

New technique for developing complex protein drugs from bacteria

Medicago reports positive interim results from preclinical trial for H7 VLP vaccine candidate

CytomX collaborates with Pfizer to develop, commercialize more effective antibody-drug conjugates

Cells with amplified HER2 gene need to be considered carefully, study says

Bioengineers find innovative ways to grow new cartilage from patient's own stem cells

EORTC BOS 2 trial to test efficacy of adding bevacizumab to peri-operative FOLFOX 4 chemotherapy

New technique selectively represses unwanted immune reactions without disabling immune system

Cancer immunotherapy shows promise in treating patients with metastatic tumors

OncoMed Pharmaceuticals highlights new data for vantictumab at ASCO meeting

Precision Biologics reports findings from Phase I/IIA study of NPC-1C at ASCO meeting

Data from Nivolumab phase I study in patients with kidney cancer to be presented at ASCO 2013

ImmunoGen presents first clinical data of IMGN853 at ASCO annual meeting

New drug shows promising results with manageable side effects for treating melanoma

Combination of ipilimumab and nivolumab drugs reduces tumor size in metastatic melanoma patients

Research: Bevacizumab fails to increase overall survival for glioblastoma patients

Study investigates gene expression signature to predict response to bevacizumab

Industry Focus eBook - Cell biology (5th edition) eBook

Latest eBooks

Industry Focus eBook - Analytical Chemistry (3rd edition)

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo